science

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..